Report
Retail’s $5B Blind Spot How GLP-1s Are Breaking Size Curves
Retail’s $5B Blind Spot examines how the rapid adoption of GLP‑1 medications is disrupting traditional apparel size curves and creating a growing risk for retailers. With more than 400 million units potentially impacted, the report explains why legacy size and demand models are failing to account for changing consumer body profiles. It presents the business case for change, outlines where the shift is happening fastest, and highlights how outdated assumptions can lead to excess inventory, lost sales, and margin erosion. The report concludes by outlining a path forward, emphasizing data‑driven and AI‑enabled approaches to help retailers adapt size strategies, reduce risk, and protect profitability as the impact of GLP‑1s accelerates.
